BRYN MAWR TRUST Co Sells 2,779 Shares of Merck & Co., Inc. (NYSE:MRK)

BRYN MAWR TRUST Co reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 1.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 188,462 shares of the company’s stock after selling 2,779 shares during the quarter. BRYN MAWR TRUST Co’s holdings in Merck & Co., Inc. were worth $15,864,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Titan Capital Management LLC CA bought a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at about $25,000. LFA Lugano Financial Advisors SA boosted its holdings in shares of Merck & Co., Inc. by 250.0% during the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock valued at $26,000 after purchasing an additional 225 shares during the last quarter. JJJ Advisors Inc. bought a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at about $27,000. Cumberland Partners Ltd bought a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at about $40,000. Finally, Fusion Family Wealth LLC boosted its holdings in shares of Merck & Co., Inc. by 268.2% during the 2nd quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock valued at $41,000 after purchasing an additional 354 shares during the last quarter. 75.02% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts recently commented on the stock. ValuEngine downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Leerink Swann assumed coverage on shares of Merck & Co., Inc. in a report on Thursday, August 15th. They issued an “outperform” rating and a $103.00 price target for the company. Bank of America assumed coverage on shares of Merck & Co., Inc. in a report on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 price target for the company. Svb Leerink assumed coverage on shares of Merck & Co., Inc. in a report on Friday, August 16th. They issued an “outperform” rating and a $103.00 price target for the company. Finally, Mizuho reaffirmed a “buy” rating and issued a $97.00 price target on shares of Merck & Co., Inc. in a report on Friday, October 18th. One analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $94.00.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 6,427 shares of the firm’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $85.09, for a total value of $546,873.43. Following the completion of the sale, the executive vice president now owns 103,223 shares of the company’s stock, valued at $8,783,245.07. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.27% of the stock is owned by company insiders.

Shares of NYSE MRK opened at $82.58 on Friday. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.21 and a quick ratio of 0.92. The company has a market cap of $208.16 billion, a P/E ratio of 19.03, a PEG ratio of 1.90 and a beta of 0.53. Merck & Co., Inc. has a 1 year low of $66.10 and a 1 year high of $87.35. The firm has a 50-day simple moving average of $83.99 and a two-hundred day simple moving average of $82.33.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.14. The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $10.94 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.06 earnings per share. As a group, equities research analysts expect that Merck & Co., Inc. will post 4.91 EPS for the current year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: Mutual Funds

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit